HIV vaccine


Also found in: Wikipedia.

HIV vaccine

AIDS As of mid-2005, there is no viable anti-HIV vaccine. See AIDS.
Mentioned in ?
References in periodicals archive ?
The report, 'Adapting to realities: Trends in HIV prevention research funding 2000 to 2008', was released at the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa, by the HIV Vaccine and Microbicide Resource Tracking Working Group.
The Elizabeth Glaser Pediatric AIDS Foundation, a world leader in the fight against pediatric AIDS, announced that it will award five grants totaling $1 million to researchers to support the development of a pediatric HIV vaccine.
Maxygen is using Monogram's Neutralizing Antibody Assay in its HIV vaccine program to rapidly and accurately screen candidate immunogens produced by gene shuffling for their ability to induce antibodies that protect against a broad range of HIV variants.
On 20 February 2007, Prime Minister Stephen Harper announced a commitment by the Government of Canada and the Bill & Melinda Gates Foundation to fund and support the Canadian HIV Vaccine Initiative (CHVI), (1) an effort to accelerate the development of an HIV/AIDS vaccine and address critical research gaps identified by the Global HIV/AIDS Vaccine Enterprise (GHAVE).
Two months after investigators halted a once-promising HIV vaccine trial, a horde of mice is delivering more bad news.
In the late 1990s, the first HIV vaccine taken to phase Ill trial, the VaxGen gpl20 vaccine (VaxGen, Brisbane, CA, USA), became the basis for substantial debate and controversy between empiricists (generally public health persons who believed that the urgency of the pandemic required taking some risks, including a potentially low-efficacy vaccine as a first step) and reductionists (generally basic scientists and researchers who felt that the gpl20 vaccine was unlikely to work given our state of knowledge and who wanted to wait for a better candidate vaccine).
As South Africa will be the first country to enrol adolescents aged 16-18 years into a phase IIb efficacy HIV vaccine trial (the HVTN 503 study), it is imperative to understand some of the challenges to adolescent enrolment in HIV vaccine trials.
The first large-scale test of concept (phase IIb) HIV vaccine trial in South Africa has been started by the South African AIDS Vaccine Initiative (SAAVI).
As a result, many participants in HIV vaccine studies will initially appear to be HIV positive on these tests.
And at the Group of Eight summit in July, Russia proposed the creation of a regional entity in eastern Europe and Central Asia to promote the development of an HIV vaccine.
The vaccine used in this study was a simplified version of an HIV vaccine now in phase II human trials in the U.
This HIV Vaccine Development meeting has gained a reputation as an important forum for presenting new data in the area of HIV research and is attended by recognized experts in the field worldwide.